IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer

被引:20
|
作者
Westeel, V.
Lebitasy, M. P.
Mercier, M.
Girard, P.
Barlesi, F.
Blanchon, F.
Tredaniel, J.
Bonnette, P.
Woronoff-Lemsi, M. C.
Breton, J. L.
Azarian, R.
Falcoz, P. E.
Friard, S.
Geriniere, L.
Laporte, S.
Lemarie, E.
Quoix, E.
Zalcman, G.
Guigay, J.
Morin, F.
Milleron, B.
Depierre, A.
机构
[1] Univ Franche Comte, CHU Besancon, Serv Pneumol, F-25030 Besancon, France
[2] IFCT, Paris, France
[3] Univ Franche Comte, Serv Biomath, F-25030 Besancon, France
[4] Ctr Mutualiste Montsouris, Paris, France
[5] APHM, Marseille, France
[6] APHP Hop St Louis, Paris, France
[7] Ctr Hosp Foch, Suresnes, France
[8] CH Versailles, Versailles, France
[9] Hop Foch, Suresnes, France
[10] Ctr Hosp Lyon Sud, HCL, F-69310 Pierre Benite, France
[11] CHU Tours, Tours, France
[12] CHU Strasbourg, F-67000 Strasbourg, France
[13] CHU Caen, F-14000 Caen, France
[14] Inst Gustave Roussy, Villejuif, France
[15] APHP Hop Tenon, Paris, France
关键词
lung cancer; post-operative follow-up; randomised trial; surgery; non-small cell lung cancer;
D O I
10.1016/S0761-8425(07)91135-3
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background The authorities advocate a minimalist attitude towards the follow-up of resected bronchial carcinoma (clinical examination and chest x-ray). A survey showed that 70% of French respiratory physicians have chosen to use the CT scanner and often endoscopy. The published data are equivocal and are often based on retrospective studies. Lung cancer is a good model for a study of post-operative surveillance. Recurrences often occur in easily observed areas, they may be detected while still asymptomatic and are sometimes potentially curable. Second primary tumours may develop at the same site. Methods The Intergroupe Francophone de Cancerologie Thoracique (IFCT) has initiated a trial comparing simple follow-up (clinical examination, chest x-ray) with a more intensive followup (CT scan, fibreoptic bronchoscopy). The surveillance will take place every 6 months for 2 years and then annually until 5 years. Expected results The main aim is to determine whether intensive follow-up improves patient survival. The opposite question is equally important. If an expensive and demanding follow-up does not affect the chances of cure these results will influence our practice.
引用
收藏
页码:645 / 652
页数:8
相关论文
共 50 条
  • [21] Phase II study of nedaplatin and irinotecan as adjuvant chemotherapy for completely resected non-small cell lung cancer
    Shuji Murakami
    Haruhiro Saito
    Tetsuro Kondo
    Hiroyuki Ito
    Fumihiro Oshita
    Kouzo Yamada
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 81 - 87
  • [22] THE RISK FACTOR OF LATE RECURRENCE IN PATIENTS WITH COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER
    Kobayashi, Yoshihisa
    Yatabe, Yasushi
    Takahashi, Osamu
    Mizuno, Tetsuya
    Kuroda, Hiroaki
    Sakakura, Noriaki
    Sakao, Yukinori
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S515 - S516
  • [23] Phase II study of nedaplatin and irinotecan as adjuvant chemotherapy for completely resected non-small cell lung cancer
    Murakami, Shuji
    Saito, Haruhiro
    Kondo, Tetsuro
    Ito, Hiroyuki
    Oshita, Fumihiro
    Yamada, Kouzo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (01) : 81 - 87
  • [24] Efficacy of Adjuvant Chemotherapy for Completely Resected Stage IB Non-Small Cell Lung Cancer
    Byun, M. K.
    Park, H. J.
    Park, H. S.
    Jeung, H.
    Cho, J. Y.
    Lee, S. S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1982 - S1982
  • [25] Biological prognostic factors for early stage completely resected non-small cell lung cancer
    Cagini, L
    Monacelli, M
    Giustozzi, G
    Moggi, L
    Bellezza, G
    Sidoni, A
    Bucciarelli, E
    Darwish, S
    Ludovini, V
    Pistola, L
    Gregorc, V
    Tonato, M
    JOURNAL OF SURGICAL ONCOLOGY, 2000, 74 (01) : 53 - 60
  • [26] A small randomized phase III single-center trial on postoperative UFT administration in patients with completely resected non-small cell lung cancer
    Ueda, H
    Sakada, T
    Kuwahara, M
    Motohiro, A
    ANTI-CANCER DRUGS, 2004, 15 (01) : 29 - 33
  • [27] Prognostic factors in patients with postoperative brain recurrence from completely resected non-small cell lung cancer
    Kanou, Takashi
    Okami, Jiro
    Tokunaga, Toshiteru
    Ishida, Daisuke
    Kuno, Hidenori
    Higashiyama, Masahiko
    THORACIC CANCER, 2015, 6 (01) : 38 - 42
  • [28] Follow-Up Update of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer
    Zhang, J-T
    Gao, X.
    Liu, S-Y
    Jiao, Z.
    Dong, S.
    Pan, Y.
    Zhou, Q.
    Zhong, W-Z
    Yang, X-N
    Yi, X.
    Wu, Y-L
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S117 - S117
  • [29] Three years follow-up of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer
    Ji, Wenhao
    Jiang, Youhua
    Li, Yuetong
    Mao, Weimin
    Teng, Lisong
    NEOPLASMA, 2024, 71 (01) : 88 - 97
  • [30] Quality of life following lobectomy or bilobectomy for non-small cell lung cancer, a two-year prospective follow-up study
    Ilonen, Ilkka K.
    Rasanen, Jari V.
    Knuuttila, Aija
    Sihvo, Eero I.
    Sintonen, Harri
    Sovijarvi, Anssi R. A.
    Salo, Jarmo A.
    LUNG CANCER, 2010, 70 (03) : 347 - 351